Efficacy of mefloquine and mefloquine-artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon region of Bolivia

Tropical Medicine and International Health

Volumn 9, Issue 2, 2004, Pages 217-221

  Avila, Juan Carlos ^a,d   Villaroel, Rodolfo ^a,d   Marquiño, Wilmer ^b   Zegarra, Jorge ^b,c   Mollinedo, René ^a,d   Ruebush, Trenton K ^c,e  

^a Prog Nac de Control de la Malaria   (Bolivia)

^b INSTITUTO NACIONAL DE SALUD   (Peru)

^c California   (Peru)

^d Min de Salud Pub y Deportes   (Bolivia)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antimalarial drug resistance; Artesunate; Bolivia; Mefloquine; Plasmodium falciparum

Indexed keywords

ARTESUNATE; MEFLOQUINE; PLASMOTRIN;

DISEASE TREATMENT; DRUG PRESCRIBING; DRUG RESISTANCE; MALARIA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BOLIVIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GAMETOCYTE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MONOTHERAPY; PARASITEMIA; PLASMODIUM FALCIPARUM; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; BOLIVIA; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MEFLOQUINE; MIDDLE AGED; PARASITEMIA; SESQUITERPENES; TREATMENT OUTCOME;

BOLIVIA; SOUTH AMERICA;

ARTESUNATE; PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 1342280406     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2003.01184.x     Document Type: Article

References (17)

1. Bruce-Chwatt LJ, Black RH, Canfield CJ, Clyde DF & Peters W (1986) Chemotherapy of Malaria. World Health Organization Monograph Series No 27, World Health Organization, Geneva.
2. Cardoso BS, Dourado HV, Pinheiro MCN et al. (1996) Estudo da eficácia e tolerância do artesunato oral isolado e em associação com mefloquina no tratamento da malaria falciparum não complicada em área endêmica do Pará, Brasil. Revista Sociedade Brasiliera de Medicina Tropical 29, 251-257.
3. Cerutti C, Durlacher RR, de Alencar FEC, Segurado AAC & Pang LW (1999) In vivo efficacy of mefloquine for the treatment of falciparum malaria in Brazil. Journal of Infectious Diseases 180, 2077-2080.
4. Marquiño WM, Huilca M, Calampa C et al. (2003) Efficacy of mefloquine and mefloquine-artesunate combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon Basin of Peru. American Journal of Tropical Medicine and Hygiene 68, 608-612.
5. Ministerio da Saúde (2001) Fundação Nacional de Saúde, Manual de terapêutica de malária. Brasilia, Brazil.
6. Ministerio de Salud y Previsión Social (2002) Manual de normas de tratamiento de la malaria, La Paz, Bolivia.
7. Na-Bangchang K, Karbwang J, Palacios PAC et al. (2000) Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. European Journal of Clinical Pharmacology 55, 743-748.
8. Nosten F, van Vugt M, Price R et al. (2000) Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356, 297-302.
9. Plowe CV, Cortese JF, Djimde A et al. (1997) Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. Journal of Infectious Diseases 176, 1590-1596.
10. Price RN, Nosten F, Luxemburger C et al. (1995) Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 89, 523-527.
11. Price RN, Nosten F, Luxemburger C et al. (1996) Effects of artemisinin derivatives on malaria transmissibility. Lancet 347, 1654-1658.
12. Simpson JA, Watkins ER, Price RN et al. (2000) Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrobial Agents and Chemotherapy 44, 3414-3424.
13. de Souza JM (1983) A phase II clinical trial of mefloquine in Brazilian male subjects. Bulletin of the World Health Organization 61, 815-820.
14. Weidekamm E, Rüsing G, Caplain H, Sörgel F & Crevoisier C (1998) Lack of bioequivalence of a generic mefloquine tablet with the standard product. European Journal of Clinical Pharmacology 54, 615-619.
15. White NJ (1998) Preventing antimalarial drug resistance through combinations. Drug Resistance Updates 1, 3-9.
16. World Health Organization (1998) The Use of Artemisinin and its Derivatives as Anti-malarial Drugs: Report of a Joint CTD/DMP/TDR Informal Consultation. WHO Document WHO/MAL/98.1086, Geneva.
17. World Health Organization (2002) Monitoring Antimalarial Drug Resistance. WHO Document WHO/CDS/EPH/2002.17, Geneva.